[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632712":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":28,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"FMF Cohort",null,"Patients diagnosed with FMF that received canakinumab for at least 6 months.",{"label":13,"type":10,"description":14,"interventionNames":10},"SJIA Cohort","Patients diagnosed with SJIA that received canakinumab for at least 6 months.",{"label":16,"type":10,"description":17,"interventionNames":10},"AOSD Cohort","Patients diagnosed with AOSD that received canakinumab for at least 6 months.",[19],{"name":20,"affiliation":20,"role":21},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[23,27],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":20,"role":24,"phone":10,"phoneExt":10,"email":10},[29],{"facility":5,"status":30,"city":31,"state":10,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":10},"RECRUITING","Basel","Switzerland","CH",{"type":35,"coordinates":36},"Point",[37,38],7.57327,47.55839,{"lat":38,"lon":37},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100632712","a-study-on-the-use-of-canakinumab-among-familial-mediterranean-fever-and-stills-disease-patients-100632712",false,"NCT07517250","A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients","Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel","Inclusion criteria:\n\n* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).\n* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.\n\nExclusion criteria:\n\n• Patients Aged \\\u003C2 Years (24 Months) at Index Date.","ALL","1 Year",{"count":52,"type":53},160,"ESTIMATED","OBSERVATIONAL","This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \\[SJIA\\] and adult-onset Still's disease \\[AOSD\\]) that received canakinumab for at least 6 months.",[57,58,59,60],"Familial Mediterranean Fever","Still Disease","Systemic Juvenile Idiopathic Arthritis","Adult-Onset Still Disease",[62,63,64,65,66,67],"Canakinumab","Real-world evidence study","Treatment patterns","Clinical outcomes","Patient quality of life","Pediatric and adult patients","2026-06-05",{"date":70,"type":71},"2026-06-09","ACTUAL",{"date":73,"type":71},"2026-03-15",{"date":75,"type":53},"2026-12-03",{"name":20,"class":6},1]